Research Study

A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)
Principal Investigator 
Vincent C. Ho

Overview

Body Locations and Systems 
Psoriasis
ClinicalTrials.gov# 
NCT01722331
Status 
Closed to Recruitment
Study Start/End 
Oct 7, 2013 to Dec 29, 2017
Locations 
Vancouver Community, Vancouver General Hospital
Name/Title 
Sze Wai Ho, Clinical Trial Coordinator
Phone 
604-875-5296
Email Address 
szewai.ho@ubc.ca
Purpose of Study 

This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous MK-3222, followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.